Usher Syndrome, Type 2A

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Usher Syndrome, Type 2A trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 2

NCT06627179

Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

The purpose of this Phase 2b study is to evaluate the safety and tolerability of ultevursen administered via intravitreal injection (IVT) in subjects with Retin…

United States81 participantsStarted 2024-12-11

Treatment: Intravitreal Injection of Ultevursen, No intervention, will not receive any active study intervention

All recent trials (9 shown)

Active — Not RecruitingNot Applicable

NCT03146078

Rate of Progression in USH2A-related Retinal Degeneration

The overall goal of this project funded by the Foundation Fighting Blindness is to characterize the natural history of disease progression in patients with USH2…

United States127 participantsStarted 2017-08-11

By InvitationNot Applicable

NCT03655223

Early Check: Expanded Screening in Newborns

Early Check provides voluntary screening of newborns for a selected panel of conditions. The study has three main objectives: 1) develop and implement an approa…

United States30,000 participantsStarted 2018-10-15

Treatment: Confirmatory Testing

Usher Syndrome, Type 2A

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

All recent trials (9 shown)

Rate of Progression in USH2A-related Retinal Degeneration

Early Check: Expanded Screening in Newborns

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

All recent trials (9 shown)

Rate of Progression in USH2A-related Retinal Degeneration

Early Check: Expanded Screening in Newborns

A New Diagnostic Paradigm for Retinitis Pigmentosa Secondary to USH2A Pathogenic Variants

An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa

Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the…

Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of…

Characterizing Rate of Progression in USHer Syndrome (CRUSH) Study

Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene